Navigation Links
Cephalon Submits Supplemental New Drug Application for FENTORA
Date:11/12/2007

ed clinical trials, opioid tolerant patients with chronic pain treated with FENTORA experienced statistically significant improvements in relief from breakthrough pain with an onset and duration of relief similar to that seen in studies of FENTORA in patients with cancer pain. The FDA's typical review period for a sNDA is 10 to 12 months.

"Breakthrough pain appears to be highly prevalent in some populations with chronic non-cancer pain, and the commitment to use an opioid to manage chronic pain should be accompanied by an effort to assess and manage the breakthrough pain as well," said Dr. Russell Portenoy, Chairman, Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, in New York City, and a principal investigator in the FENTORA clinical trials. "New treatment options that specifically target breakthrough pain are welcome, and are likely to improve the clinician's ability to address this problem effectively."

About Breakthrough Pain

Millions of Americans suffer from chronic pain, a condition that often consists of two distinct components: persistent pain, which is pain that is continuous throughout the day, and breakthrough pain, which is a transitory flare of moderate-to-severe pain in patients with otherwise managed persistent pain. Breakthrough pain can reach peak intensity in as little as three minutes and typically lasts for 30 to 60 minutes. It may occur during a specific activity, spontaneously with no apparent cause, or when the dose of the persistent pain medicine wears off.

About FENTORA

Approved in September 2006, FENTORA is the first tablet formulation of the opioid fentanyl and the first new medication approved for the management of breakthrough pain in opioid tolerant patients with cancer since 1998. Its proprietary OraVescent(R) drug delivery system was developed by Cephalon subsidiary CIMA LABS. FENTORA is covered by patents until 2019.

The sugar-free FENTORA tablet is placed between the ch
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
9. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
10. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
11. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... - SQI Diagnostics Inc. (TSX-V: SQD), a life sciences company ... advanced microarray diagnostics, today announced it will hold an ... pm ET.  During the call, ... of SQI,s recent commercialization progress and then introduce Dr. ... appointed to the Board of Directors of SQI and ...
(Date:8/18/2014)... YORK , August 18, 2014 ... published by Transparency Market Research "Life Science Reagents ... Flow Cytometry, Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents and ... and Academic Institutions, Clinical Laboratories, and Forensic Laboratories)- ... Forecast, 2013 - 2019", the global life science ...
(Date:8/18/2014)... 18. August 2014 Vier führende ... internationale klinische Studie auf, in der eine ... soll das Sehvermögen bei allen Entfernungen verbessern, ... möglicherweise keine Lese- oder Gleitsichtbrille mehr benötigen. ... FluidVision Accommodating Intraocular Lens (FluidVision ...
(Date:8/15/2014)... FOREST, Ill. , Aug. 15, 2014   ... world,s leading provider of injectable drugs and infusion technologies, ... Morgan Stanley Global Healthcare Conference on Tuesday, Sept. 9, ... The presentation is scheduled to begin at 11:45 ... will be available to all interested parties through a ...
Breaking Biology Technology:SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... when theoretical work is eventually supported by experimentation. Such ... Italian and US scientists when they received preliminary confirmation ... that is currently orbiting the Earth on the Foton-M3 ... week ago, the scientists are already very excited about ...
... Board Reflects Emphasis on Drug Development and Recent ... ... Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) announced several changes to ... drug development and the completion of a major strategic financing,with ...
... NanoBio(R) Corporation, a,biopharmaceutical company developing novel anti-infective ... infections, today announced,the addition of four new scientists ... PharmD, Ph.D.; Susan Ciotti, Ph.D.; Robert L. Hagan, ... developing and commercializing,its novel topical anti-infectives and mucosal ...
Cached Biology Technology:Fluid theory confirmed by Foton 2Lexicon Appoints Judith Swain, M.D. to Board of Directors 2Lexicon Appoints Judith Swain, M.D. to Board of Directors 3Lexicon Appoints Judith Swain, M.D. to Board of Directors 4NanoBio Expands Drug Development Team for Its Anti-Infective Products 2NanoBio Expands Drug Development Team for Its Anti-Infective Products 3
(Date:8/19/2014)... Aug. 19, 2014 To improve students, chances ... grades, the University of Houston (UH) implemented a ... students at risk for failure. , Through ... Board (THECB), the Department of Biology and Biochemistry ... students taking "General Biology" for non-majors and "Introductory ...
(Date:8/19/2014)... is available in German . ... intermittent energy sources. If a large amount of electricity is ... excess energy will have to be stored during productive periods ... storage capacities are far from adequate for the purpose. Science ... important focus lies on battery systems that used to be ...
(Date:8/19/2014)... lemur. It,s not an African Bush Baby or even a ... downright "cool" primate from Southeast Asia. , "It,s really not ... Brown, curator-in-charge at the University of Kansas, Biodiversity Institute. "A ... body; a long tail with a furry tuft at the ... a bit like the disks on the digits of tree ...
Breaking Biology News(10 mins):University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3
... by global warming can prove extremely destructive to island habitats, ... C. Bellard, C. Leclerc and F. Courchamp of the ... possible scenarios, from optimistic to very pessimistic, to bring attention ... biodiversity hotspots worldwide. The study was published in the open ...
... measures carbon dioxide and suggests that far from being a ... a biological signalling molecule. Researchers led by Professor Nick ... of Warwick have shown that the body senses carbon dioxide ... receptor for the gas. Connexin 26 is better known as ...
... largest lake in Britain and Ireland, Lough Neagh, has lost ... to researchers at Queen,s University Belfast., The study by Quercus, ... number of diving ducks migrating to the lake for the ... in the space of a decade., The research, published in ...
Cached Biology News:Island biodiversity in danger of total submersion with climate change 2Carbon dioxide's new-found signalling role could be applied to blood flow, birth and deafness 2Largest lake in Britain and Ireland has lost three-quarters of winter water birds 2
5-bromouridine 5'-triphosphate (BrUTP) *10 mM in TE buffer*...
...
in vitro Translation, Accessory Products...
... The GenoStat Inducible Expression System provides tightly ... mammalian cells and is capable of repeated ... is mediated by the highly specific interaction ... bipartite nuclear receptor complex. Gene expression levels ...
Biology Products: